PPBT vs. KPRX, MNPR, IMNN, RDHL, AVTX, PIRS, ELAB, AKTX, MBRX, and MIRA
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Kiora Pharmaceuticals (KPRX), Monopar Therapeutics (MNPR), Imunon (IMNN), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Elevai Labs (ELAB), Akari Therapeutics (AKTX), Moleculin Biotech (MBRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
In the previous week, Purple Biotech's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.
Purple Biotech has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
Purple Biotech and Kiora Pharmaceuticals both received 12 outperform votes by MarketBeat users. However, 92.31% of users gave Purple Biotech an outperform vote while only 66.67% of users gave Kiora Pharmaceuticals an outperform vote.
Purple Biotech's return on equity of -57.40% beat Kiora Pharmaceuticals' return on equity.
9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Purple Biotech currently has a consensus target price of $9.00, indicating a potential upside of 1,511.46%. Kiora Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 1,330.03%. Given Purple Biotech's higher possible upside, research analysts clearly believe Purple Biotech is more favorable than Kiora Pharmaceuticals.
Summary
Purple Biotech beats Kiora Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Purple Biotech Competitors List
Related Companies and Tools
